{"prompt": "[\"Appendix 3: Healthcare Professional Reported Outcome Measures (cont'd)\", 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '122 / Protocol MO40628, Version 12']['Appendix 4', 'American Cancer Society / American Society of Clinical Oncology', 'Breast Cancer Survivorship Care Guideline', 'Available at:', 'http://ascopubs.org/doi/abs/10.1200/JCO.2015.64.3809?url_ver=', '2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '123 / Protocol MO40628, Version 12']['Appendix 5', 'Eastern Cooperative Oncology Group Performance Status Scale', 'Grade', 'Description', '0', 'Fully active, able to carry on all pre-disease performance without restriction', '1', 'Restricted in physically strenuous activity but ambulatory and able to carry out work', 'of a light or sedentary nature, e.g., light housework or office work', '2', 'Ambulatory and capable of all self-care but unable to carry out any work activities.', 'Up and about > 50% of waking hours', '3', 'Capable of only limited self-care, confined to a bed or chair > 50% of waking hours', '4', 'Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair', '5', 'Dead', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '124 / Protocol MO40628, Version 42']\n\n###\n\n", "completion": "END"}